atazanavir (Reyataz, ATV/r)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Reyataz (FDA approved 2003)

Indications

Contraindications

Dosage

* take with food, absorption requires food & gastric acidity[6]

Tabs: 150, 200, 300 mg

Pharmacokinetics

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

Component of

References

  1. Prescriber's Letter 10(8):45 2003
  2. Department of Veterans Affairs, VA National Formulary
  3. Chan-Tack KM et al Atazanavir-associated nephrolithiasis: Cases from the Food and Drug Administration's Adverse Event Reporting System. AIDS 2007, 21:1215 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17502736
  4. 4.0 4.1 Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016)
  5. 5.0 5.1 5.2 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for atazanavir and UGT1A1 https://www.pharmgkb.org/guideline/PA166128738Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for atazanavir and UGT1A1 https://www.pharmgkb.org/guideline/PA166128738
  6. 6.0 6.1 6.2 Medical Knowledge Self Assessment Program (MKSAP) 17, 18 American College of Physicians, Philadelphia 2015, 2018

Database